Author: admin

Administrator

Augmented Intelligence in Life Sciences and Healthcare: What Your Data Can Show You (While You Decide What To Do)

Augmented Intelligence in Life Sciences and Healthcare: What Your Data Can Show You (While You Decide What To Do)

Gunnar Carlsson

Artificial intelligence is rapidly developing in many domains, including life sciences and health care. The broader notion of augmented intelligence, where machines interact with humans, is of a great deal of importance. Data sets in life sciences and healthcare are large and complex to the point of being beyond human comprehension.

What if you could “see” the shape of this data in its purest topological form, and interrogate it from this vantage point not achievable with conventional analysis methods? What might you find? What new discoveries might you make? And what might you do next?

Tonight’s talk from Gunnar Carlsson, mathematics Professor Emeritus at Stanford University and co-founder of Ayasdi, will feature examples of a methodology called Topological Data Analysis (TDA) applied to life sciences and healthcare data of a variety of types and sources. This approach has been developing rapidly in the last ten years, supports augmented intelligence, and does not require annotated data.

Case studies of data and derived insights for next step decision-making include:

– stratifying asthma and diabetes based on genomic and phenotypic/EMR data
– identifying optimal clinical care paths for knee replacement and bowel surgery based on variations detected in physician protocol and patient outcomes
– the progression of infectious disease
– the relationship of fMRI data with temporal information about tasks and task transitions

Attention will be given to the process used to examine the data, and how to decide what to do next.

Didn’t see your use case covered? Bring your questions. Whether you are an investigator, drug or device developer, clinician, regulatory professional, basic scientist, or other with a life sciences interest, all questions are welcome at our extended Q&A.

 

 

 

To see this content, please login

How to Grow Your Scientific Business from Referrals Only to Sales Ready

How to Grow Your Scientific Business from Referrals Only to Sales Ready
Bindu Joshi
CEO & Founder
Josh.i
We will be discussing business growth strategies that scientific businesses can use to grow their business from referrals only to commercial ready. Many scientific businesses are typically owned by scientists (not businessmen/women), and offer innovative, niche services/products that they’re uniquely skilled at and passionate about. We’re neither trained nor interested in learning the skills of running a business. So, over time, the demands of running the business lead to overwhelm, frustration and stress. We will discuss strategies and tactics for business growth to get out of this grind and enjoy your business success.

 

To see this content, please login

The Apple Heart Study: Transforming clinical trial conduct.

The Apple Heart Study: Transforming clinical trial conduct.

Ken Mahaffey, MD

October 8, 2019
6-9PM, Wilson Sonsini Goodrich & Rosati

The Apple Heart Study was a pragmatic, virtual study of over 400,000 participants to evaluate the Apple Watch ability to detect irregular heart rhythms. The innovative design and operational success will be discussed and the results presented.

Dr. Mahaffey is the Vice-Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR). SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials. SCCR has expertise in mobile and digital technology investigation. Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation.

Dr. Mahaffey also studies the methodology of clinical trials including the standardization of the definition of MI used in clinical trials, the adjudication of clinical endpoints, and the evaluation of evidence-based operations. He works with the FDA and chaired the MI and Death Definitions Working Group in the Standardized Data Collection for Cardiovascular Trials Initiative. Dr. Mahaffey is a member of the Stanford University Institutional Review Board.

Event Speaker Bio:

Dr. Mahaffey is the Vice Chair of Clinical Research in the Department of Medicine at Stanford University and the Director of the Stanford Center for Clinical Research (SCCR). SCCR is an academic research organization to support researchers to design and conduct clinical research studies and to enroll Stanford patients in clinical trials. SCCR has expertise in mobile and digital technology investigation. Dr. Mahaffey’s own research focuses on the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. His research efforts have resulted in the approval of new therapies for the treatment of patients with acute coronary syndromes, diabetes, and atrial fibrillation. Dr. Mahaffey also studies the methodology of clinical trials including the standardization of the definition of MI used in clinical trials, the adjudication of clinical endpoints, and the evaluation of evidenced-based operations. He works with the FDA and chaired the MI and Death Definitions Working Group in the Standardized Data Collection for Cardiovascular Trials Initiative. Dr. Mahaffey is a member of the Stanford University Institutional Review Board.

To see this content, please login